Expected earnings - InMed Pharmaceuticals Inc.

Stock Information for InMed Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.